Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases

Yohann Loriot,Lance C. Pagliaro,Aude Flechon,J. Mardiak,Lionnel Geoffrois,Pierre Kerbrat,Christine Chevreau,R. Delva,F. Rolland,Christine Theodore,Guilhem Roubaud,Gwenaelle Gravis,Jean-Christophe Eymard,Jean-Pierre Malhaire,C. Linassier,Muriel Habibian,Anne-Laure Martin,Florence Journeau,Maria Reckova,Christopher J. Logothetis,Agnès Laplanche,G. Le Teuff,S. Culine,Karim Fizazi

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases

2017

• The Groupe d'etude des tumeurs urogenitales (GETUG) 13 phase III trial demonstrated that a dose-dense regimen improves progression-free survival in patients with an unfavourable decline.

Keywords:

Regimen
Pathology
Germ cell
Medicine
Radiography
Etoposide
Cisplatin
Bleomycin
poor prognosis
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations